{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-017821","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2026-05-19T21:26:35+00:00","discovered_at":"2026-05-19T21:28:28.352967+00:00","generated_at":"2026-05-19T21:30:38.673874+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Monopar announces Phase 2 publication: ALXN1840 improves copper balance in Wilson disease","bullets":["Cumulative mean decrease in copper balance of -6.08 mg over 21 days (95% CI: -10.18 to -1.98 mg).","Mean daily change of -0.37 mg (p=0.005) on 15 mg/day dosing; -0.29 mg (p=0.023) overall.","~50% increase in fecal copper output-to-intake ratio vs baseline (p=0.041).","ALXN1840 well tolerated; no serious adverse events reported in the single-arm Phase 2 trial.","Improvements seen even in patients with mean 16 years prior standard-of-care treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-017821","json":"https://secwatch.observer/filing/0001437749-26-017821.json","markdown":"https://secwatch.observer/filing/0001437749-26-017821.md","text":"https://secwatch.observer/filing/0001437749-26-017821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926017821/0001437749-26-017821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926017821/mnpr20260513_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T21:30:38.673874+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}